Bigfoot Biomedical said today that it inked a commercial supply deal to include Owen Mumford‘s Pentips line of pen needles with Bigfoot’s injection system subscription bundles.
Milpitas, Calif.-based Bigfoot is working on monthly subscription packages for people with insulin-requiring diabetes. The company said it selected Owen Mumford’s pen needle because of the needle’s compatibility with all disposable insulin pens and availability in popular lengths and gauges.
“As a company comprised of people who live with diabetes, we know that one of the largest, non-therapy related burdens people face is the acquisition and management of diabetes supplies,” Bigfoot Biomedical co-founder & CEO, Jeffrey Brewer said in prepared remarks. “Our inclusion of Owen Mumford’s Pentips in our supply bundles will ensure our customers always have access to a high quality, comfortable pen needle for each insulin dose.”
“We’re delighted to support Bigfoot’s innovative product and service vision for its injection systems with our Pentips line,” Owen Mumford’s EVP, Travis Shaw, added. “We look forward to a strong relationship built on shared commitments to providing quality products for insulin pen users.”
Bigfoot is developing a platform designed to support insulin delivery for people with insulin-requiring diabetes who use injections and infusion pumps.
The company is slated to launch its first two products, Bigfoot Inject and Bigfoot Loop, in 2020 – contingent upon finishing a pivotal clinical trial and winning regulatory approvals.
Earlier this year, Bigfoot entered into a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices.
